72
Participants
Start Date
September 9, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
MI078 capsule dose 1
MI078 capsule dose 1 for 3 days
MI078 capsule dose 2
MI078 capsule dose 2 for 3 days
placebo
placebo for 3 days
Beijing HuiLongGuan Hospital, Beijing
Shanghai Mental Health Center, Shanghai
Shanghai Pudong New Area Mental Health Center, Shanghai
The Affiliated Beijing Anding Hospital of Capital Medical University, Wuhu Hospital, Wuhu
The First People's Hospital of Hangzhou, Hangzhou
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
The Affiliated Kangning Hospital of Ningbo University, Ningbo
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The First Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Jinan University, Guangzhou
Shunde Hospital of Southern Medical University, Foshan
Guangxi Zhuang Autonomous Region People's Hospital, Nanning
The People's Hospital of Guizhou Province, Guiyang
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu
First Affiliated Hospital of Kunming Medical University, Kunming
Xiamen Xian Yue Hospital, Xiamen
The First Affiliated Hospital of Ningbo University, Ningbo
The First Hospital of Hebei Medical University, Shijiazhuang
Xingtai People's Hospital, Xingtai
Linfen Central Hospital, Linfen
The First Hospital of Shanxi Medical University, Taiyuan
Nanjing Minova Pharmaceutical Co., Ltd.
INDUSTRY